marstacimab
Selected indexed studies
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. (Blood, 2025) [PMID:40608864]
- Marstacimab: First Approval. (Drugs, 2025) [PMID:39715914]
- Marstacimab. (, 2006) [PMID:39626039]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. (2025) pubmed
- Marstacimab: First Approval. (2025) pubmed
- Marstacimab. (2006) pubmed
- Hympavzi (Marstacimab-hncq). (2025) pubmed
- A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. (2023) pubmed
- Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. (2023) pubmed
- Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. (2026) pubmed
- Marstacimab-hncq. (2025) pubmed
- Marstacimab for the Treatment of Hemophilia A or B. (2025) pubmed
- Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis. (2025) pubmed